Syndax Pharmaceuticals (SNDX) News Today $13.08 +0.08 (+0.62%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Assenagon Asset Management S.A. Buys 1,598,428 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Assenagon Asset Management S.A. raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 343.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,064,456 shares of the company's stockJanuary 17 at 4:09 AM | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest UpdateSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 21,310,000 shares, an increase of 30.3% from the December 15th total of 16,360,000 shares. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is currently 10.7 days.January 16 at 8:18 PM | marketbeat.comIncyte And Syndax : FDA Approves Niktimvo 9 Mg And 22 Mg Vial SizesJanuary 16 at 5:07 AM | markets.businessinsider.comIncyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vialsJanuary 16 at 5:07 AM | msn.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America SecuritiesJanuary 16 at 5:07 AM | markets.businessinsider.comIncyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesJanuary 15 at 5:34 PM | prnewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week Low - What's Next?Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year Low - Time to Sell?January 14, 2025 | marketbeat.comSyndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | prnewswire.comInvesting in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gainJanuary 10, 2025 | finance.yahoo.comScotiabank Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $16.00January 10, 2025 | americanbankingnews.comSyndax price target lowered to $16 from $18 at ScotiabankJanuary 9, 2025 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)January 9, 2025 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at ScotiabankScotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Wednesday.January 8, 2025 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmJanuary 7, 2025 | prnewswire.comSyndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | prnewswire.comBank of America Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)January 7, 2025 | markets.businessinsider.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 3, 2025 | prnewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1% - Here's What HappenedSyndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.1% Higher - Here's WhyDecember 31, 2024 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmDecember 29, 2024 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buyDecember 28, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year Low - What's Next?Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week Low - Should You Sell?December 26, 2024 | marketbeat.comGeode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Geode Capital Management LLC grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,977,082 shares of the company's stock after purchasinDecember 25, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6% - Here's WhySyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 2.6% - What's Next?December 24, 2024 | marketbeat.comBarclays PLC Raises Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Barclays PLC raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 143.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 187,629 shares of the company's stock after purchasing an additional 110,535 sDecember 23, 2024 | marketbeat.comSyndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvalsDecember 22, 2024 | uk.investing.comBarclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)December 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of DirectorsDecember 19, 2024 | prnewswire.comFranklin Resources Inc. Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Franklin Resources Inc. grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 13.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,763,277 shares of the compDecember 19, 2024 | marketbeat.comJ.P. Morgan Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)December 19, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year Low - Should You Sell?Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year Low - Should You Sell?December 18, 2024 | marketbeat.comState Street Corp Has $72.59 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)State Street Corp boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,770,826 shares of the company's stockDecember 18, 2024 | marketbeat.comShort Interest in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Rises By 35.8%Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 14,400,000 shares, an increase of 35.8% from the November 15th total of 10,600,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is currently 9.7 days.December 15, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Should You Sell?Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Should You Sell?December 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Y Intercept Hong Kong Ltd boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 319.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,302 shares of tDecember 11, 2024 | marketbeat.comSyndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday.December 10, 2024 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Holdings Trimmed by Wellington Management Group LLPWellington Management Group LLP lessened its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 32.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,985,976 shares of theDecember 10, 2024 | marketbeat.comTwo Sigma Advisers LP Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Two Sigma Advisers LP grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 669,352 shares of the company's stock after acquiring an additional 48,100 shares durDecember 10, 2024 | marketbeat.comPositive Outlook for Syndax Pharmaceuticals Amid Efficacy and Safety ConsiderationsDecember 9, 2024 | markets.businessinsider.comSyndax announces additional positive data from AUGMENT-101 trial of RevuforjDecember 9, 2024 | markets.businessinsider.comSyndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialDecember 9, 2024 | prnewswire.comCharles Schwab Investment Management Inc. Acquires 41,458 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Charles Schwab Investment Management Inc. increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 6.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,947 shaDecember 9, 2024 | marketbeat.comSyndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingDecember 7, 2024 | prnewswire.comVerition Fund Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Verition Fund Management LLC trimmed its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 45.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79,341 shares of the company's stock after selDecember 7, 2024 | marketbeat.comBuy Recommendation on Syndax Pharmaceuticals: Revumenib’s Market Potential and Upcoming CatalystsDecember 6, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Sells 67,086 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Point72 Asset Management L.P. lowered its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,778,267 shares of the company's stock after selling 67,086 shares dDecember 5, 2024 | marketbeat.comWhy Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 5, 2024 | msn.comParkman Healthcare Partners LLC Trims Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Parkman Healthcare Partners LLC trimmed its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 15.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 508,283 shares of the company'December 4, 2024 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comEventide Asset Management LLC Acquires New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Eventide Asset Management LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 786,990 shares of the company's stock, valued aNovember 29, 2024 | marketbeat.comSyndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNovember 27, 2024 | prnewswire.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.450.64▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼95▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VKTX News TGTX News KRYS News AXSM News OGN News SRRK News ALVO News RARE News ADMA News VRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts